Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Caris' MI Profile; Life Technologies' Ion AmpliSeq Panels; CHOP's 1:1000 Mito-Plus

Premium

Caris Life Sciences has launched MI Profile, a next-generation sequencing-based tumor profiling assay. The assay matches potential therapies to patient-specific biomarker information. Oncologists are provided reports indicating which available therapies are potentially effective, along with those that are potentially less effective, as well as information on appropriate clinical trials for the patient.


Life Technologies' Ion Torrent has released several disease-specific Ion AmpliSeq panels, including one for colon and lung cancer, a BRCA1/2 panel, a TP53 panel, a cystic fibrosis panel, a cardiovascular disease panel and an AML panel.

The panels are for research use only. They are available for review on the company's website and will soon be available to order.



The
Children's Hospital of Philadelphia has launched its 1:1000 Mito-Plus Whole-Exome test. The test is for children with mitochondrial disease of unknown causes and sequences the protein coding regions of the mitochondrial genome.

The Wellcome Trust Sanger Institute has released version 63 of COSMIC, the Catalog of Somatic Mutations in Cancer. The latest release includes the full curation of genes STAT3 and TNFRSF14, together with further FGFR and EWSR1 fusion gene pairs.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.